Risk factors for geographic atrophy after intravitreal ranibizumab injections for retinal angiomatous proliferation.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  American journal of ophthalmology-glaucoma

• Publication date

  2015-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ajo.2014.10.035PMID 25447115
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials.

  2015cited by this paper
• Macular choroidal thickness and volume of eyes with reticular pseudodrusen using swept-source optical coherence tomography.

  2014cited by this paper
• INCIDENCE AND CHARACTERISTICS OF NEOVASCULARIZATION IN FELLOW EYES OF JAPANESE PATIENTS WITH UNILATERAL RETINAL ANGIOMATOUS PROLIFERATION

  2014cited by this paper
• Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials.

  2014cited by this paper
• Long-term results of intravitreal ranibizumab for the treatment of retinal angiomatous proliferation and utility of an advanced RPE analysis performed using spectral-domain optical coherence tomography

  2014cited by this paper
• Geographic atrophy: clinical features and potential therapeutic approaches.

  2014cited by this paper
• Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation

  2013cited by this paper
• Reproducibility of subfoveal choroidal thickness measurements with enhanced depth imaging by spectral-domain optical coherence tomography.

  2013cited by this paper
• Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial.

  2013cited by this paper
• Characteristics of incident geographic atrophy in the complications of age-related macular degeneration prevention trial.

  2013cited by this paper
• SENSITIVITY AND SPECIFICITY OF DETECTING RETICULAR PSEUDODRUSEN IN MULTIMODAL IMAGING IN JAPANESE PATIENTS

  2013cited by this paper
• Cuticular drusen: stars in the sky.

  2013cited by this paper
• Thinner choroid and greater drusen extent in retinal angiomatous proliferation than in typical exudative age-related macular degeneration.

  2013cited by this paper
• Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials.

  2013cited by this paper
• Prevalence and genomic association of reticular pseudodrusen in age-related macular degeneration.

  2013cited by this paper
• Subfoveal choroidal thickness: the Beijing Eye Study.

  2013cited by this paper
• Correlation between subfoveal choroidal thickness and the severity or progression of nonexudative age-related macular degeneration.

  2013cited by this paper
• Choroidal changes associated with reticular pseudodrusen.

  2012cited by this paper
• Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.

  2012cited by this paper
• Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials.

  2012cited by this paper
• GEOGRAPHIC ATROPHY IN RETINAL ANGIOMATOUS PROLIFERATION

  2011cited by this paper
• Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials.

  2011cited by this paper
• Ranibizumab for retinal angiomatous proliferation in age-related macular degeneration

  2010cited by this paper
• The multifunctional choroid.

  2010cited by this paper
• An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris

  2009cited by this paper
• Reticular macular disease.

  2009cited by this paper
• INTRAVITREAL BEVACIZUMAB AS PRIMARY TREATMENT FOR RETINAL ANGIOMATOUS PROLIFERATION: Twelve-Month Results

  2009cited by this paper
• Clinical characteristics of exudative age-related macular degeneration in Japanese patients.

  2007cited by this paper
• Types of choroidal neovascularisation in newly diagnosed exudative age-related macular degeneration

  2007cited by this paper
• RETINAL ANGIOMATOUS PROLIFERATION IN AGE–RELATED MACULAR DEGENERATION

  2001cited by this paper
• RETICULAR PSEUDODRUSEN: A Risk Factor in Age-Related Maculopathy

  1995cited by this paper

• Analysis of macular atrophy in type 3 macular neovascularization cases: a follow-up of over 7 years.

  2026cites this paper
• One-year results of the intravitreal administration of faricimab in patients with naïve type 3 macular neovascularization

  2026cites this paper
• Enhanced retinal pigment epithelial cells as a delivery vehicle for retinal disease

  2025cites this paper
• Comparative Efficacy of Brolucizumab and Aflibercept in Polypoidal Choroidal Vasculopathy: A Systematic Review and Meta-Analysis

  2025cites this paper
• Subretinal Hyperreflective Material, Atrophy, and Intraretinal Fluid in Pachychoroid Neovasculopathy.

  2025cites this paper
• Long-term outcomes and the association between early detection of retinal pigment epithelial atrophy and remission after loading dose in eyes with retinal angiomatous proliferation

  2025cites this paper
• Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis.

  2025cites this paper
• Functional and structural characteristics in patients with type 3 macular neovascularisation treated with anti-VEGF. Three-year results in real world settings

  2024influential citation
• Intravitreal anti-vascular endothelial growth factor and combined photodynamic therapy for pachychoroid neovasculopathy: long-term treatment outcomes

  2024cites this paper
• Type 3 MNV in AMD: baseline predictors of 3-year macular atrophy development.

  2024cites this paper
• Review of type 3 macular neovascularization in age-related macular degeneration: no DRAMA (Deep Retinal Age-related Microvascular Anomalies)

  2024cites this paper
• Inter-Reader and Inter-Modality Variability in Macular Atrophy Quantification in Neovascular AMD: Comparison of Six Imaging Modalities.

  2024cites this paper
• Effect of Pro Re Nata Regimen with Anti-VEGF on Type 3 Macular Neovascularization: Long-Term Outcomes

  2024cites this paper
• Assistance Burden Comparison Between Age-Related Macular Degeneration and Retinal Angiomatous Proliferation Over a Three-Year Follow-up.

  2024cites this paper
• Long term follow up of patients with MNV3 treated with intra-vitreal Aflibercept

  2024cites this paper
• Intravitreal Brolucizumab and Aflibercept for Polypoidal Choroidal Vasculopathy

  2023cites this paper
• Efficacy and safety of different conbercept injection regimens in the treatment of choroidal neovascularization in pathological myopia: a retrospective study

  2023cites this paper
• Treat-and-extend dosing of intravitreal anti-VEGF agents in neovascular age-related macular degeneration: a meta-analysis

  2023cites this paper
• Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes

  2022cites this paper
• Essential Role of Multi-Omics Approaches in the Study of Retinal Vascular Diseases

  2022cites this paper
• Neovascular age-related macular degeneration without exudative recurrence over 24 months after initial remission

  2022cites this paper
• Neovascular age-related macular degeneration in which exudation predominantly occurs as a subretinal fluid during anti-vascular endothelial growth factor treatment

  2022cites this paper
• FLUID-BASED VISUAL PROGNOSTICATION IN TYPE 3 MACULAR NEOVASCULARIZATION-FLIP-3 STUDY

  2021cites this paper
• An integrated analysis of clinical and morphometric indications of atrophic forms of age-related macular degeneration

  2021cites this paper
• Impact of macular fluid features on outcomes of anti-vascular endothelial growth factor treatment for type 3 macular neovascularization

  2021cites this paper
• Reticular pseudodrusen: A critical phenotype in age-related macular degeneration.

  2021cites this paper
• Development of Macular Atrophy in Patients with Wet Age-Related Macular Degeneration Receiving Anti-VEGF Treatment

  2021cites this paper
• The Use of Neuroprotective Agents in Treating Geographic Atrophy

  2021cites this paper
• Using optical coherence tomography angiography to guide myopic choroidal neovascularization treatment: a 3-year follow-up study

  2021cites this paper
• GEOGRAPHIC ATROPHY INCIDENCE AND PROGRESSION AFTER INTRAVITREAL INJECTIONS OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS FOR AGE-RELATED MACULAR DEGENERATION

  2021cites this paper
• Macular ganglion cell complex changes in eyes treated with aflibercept for neovascular age-related macular degeneration.

  2021cites this paper
• Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy

  2021cites this paper
• Assessing the long-term evolution of type 3 neovascularization in age-related macular degeneration using optical coherence tomography angiography

  2021cites this paper
• Incidence and Progression of Nongeographic Atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Clinical Trial.

  2020cites this paper
• Brolucizumab: an evolution in treatment for neovascular age-related macular degeneration

  2020cites this paper
• Fundus autofluorescence of retinal angiomatous proliferation

  2020cites this paper
• LONG-TERM CHANGES IN CHOROIDAL THICKNESS IN EYES WITH TYPE 3 MACULAR NEOVASCULARIZATION

  2020cites this paper
• Progression of macular atrophy in patients undergoing anti‐vascular endothelial growth factor therapy for neovascular age‐related macular degeneration

  2020influential citation
• Different conbercept injection strategies for the treatment of exudative age-related macular degeneration

  2020cites this paper
• Clinical outcomes of 1 + PRN and 3 + Q3M regimens of intravitreal conbercept injection for exudative age-related macular degeneration

  2020cites this paper
• Spectral-Domain OCT Analysis of Risk Factors for Macular Atrophy Development in the HARBOR Study for Neovascular Age-Related Macular Degeneration.

  2020cites this paper
• Age-Related Macular Degeneration (AMD): Non-neovascular and Neovascular AMD

  2020cites this paper
• Changes in inner retinal layer thickness in patients with exudative age-related macular degeneration during treatment with anti-vascular endothelial growth factor

  2020cites this paper
• Changes in the Ganglion Cell-inner Plexiform Layer after Consecutive Intravitreal Injections of Anti-vascular Endothelial Growth Factor in Age-related Macular Degeneration Patients

  2020cites this paper
• A Review of Macular Atrophy of the Retinal Pigment Epithelium in Patients with Neovascular Age-Related Macular Degeneration: What is the Link? Part II

  2020cites this paper
• CHANGES IN OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY AND DISEASE ACTIVITY IN TYPE 3 NEOVASCULARIZATION AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT.

  2020cites this paper
• Retinal pigment epithelial atrophy after anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy

  2020cites this paper
• Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).

  2019cites this paper
• Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Pachychoroid Neovasculopathy

  2019cites this paper
• Fellow Eye Status Is a Biomarker for the Progression Rate of Geographic Atrophy: A Systematic Review and Meta-analysis.

  2019cites this paper
• Retinal and Choroidal Changes after Anti Vascular Endothelial Growth Factor Therapy for Neovascular Age-related Macular Degeneration.

  2019cites this paper
• One-Year Results of Fixed Aflibercept Treatment Regime in Type 3 Neovascularization

  2019cites this paper
• Focal retinal pigment epithelium atrophy at the location of type 3 neovascularization lesion: a morphologic feature associated with low reactivation rate and favorable prognosis

  2019cites this paper
• Intravitreal Aflibercept for Retinal Angiomatous Proliferation: Results of a Prospective Case Series at 96 Weeks

  2019cites this paper
• Long-Term Incidence and Growth of Chorioretinal Atrophy in Patients with Polypoidal Choroidal Vasculopathy

  2019cites this paper
• Topographic Correspondence of Macular Atrophy With Choroidal Neovascularization in Ranibizumab-treated Eyes of the TREX-AMD Trial.

  2018cites this paper
• Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.

  2018cites this paper
• Factors influencing macular atrophy growth rates in neovascular age-related macular degeneration treated with ranibizumab or aflibercept according to an observe-and-plan regimen

  2018cites this paper
• Subretinal drusenoid deposits AKA pseudodrusen.

  2018cites this paper
• Incidence et facteurs de risque des pseudodrusen réticulés : l’étude ALIENOR

  2018cites this paper
• Short-term efficacy of intravitreal Aflibercept injections for retinal angiomatous proliferation

  2017cites this paper
• INTRAVITREAL AFLIBERCEPT AND RANIBIZUMAB INJECTIONS FOR TYPE 3 NEOVASCULARIZATION

  2017cites this paper
• Macular Atrophy Development and Subretinal Drusenoid Deposits in Anti-Vascular Endothelial Growth Factor Treated Age-Related Macular Degeneration

  2017influential citation
• Retinal angiomatous proliferation.

  2017cites this paper
• [Choroidal Neovascularisation Other than Typical Neovascular Age-Related Macular Degeneration].

  2017cites this paper
• MACULAR ATROPHY AND MACULAR MORPHOLOGY IN AFLIBERCEPT-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

  2017cites this paper
• Patchy Chorioretinal Atrophy Changes at the Posterior Pole After Ranibizumab for Myopic Choroidal Neovascularization.

  2017cites this paper
• Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial.

  2017cites this paper
• INCIDENCE AND CAUSES OF VISION LOSS DURING AFLIBERCEPT TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: One-Year Follow-up

  2017cites this paper
• Rate of Macular Ganglion Cell-inner Plexiform Layer Thinning in Glaucomatous Eyes With Vascular Endothelial Growth Factor Inhibition

  2017cites this paper
• Spotlight on reticular pseudodrusen

  2017cites this paper
• An 8‐year follow‐up of anti‐vascular endothelial growth factor treatment with a treat‐and‐extend modality for neovascular age‐related macular degeneration

  2017cites this paper
• Retinal Pigment Epithelial Detachment in Retinal Angiomatous Proliferation

  2017cites this paper
• RECURRENCE IN PATIENTS WITH TYPE 3 NEOVASCULARIZATION (RETINAL ANGIOMATOUS PROLIFERATION) AFTER INTRAVITREAL RANIBIZUMAB

  2017cites this paper
• Sonderformen choroidaler Neovaskularisationsmembranen

  2017cites this paper
• Antiangiogenic activity of PLGA-Lupeol implants for potential intravitreal applications.

  2017cites this paper
• Sex Age VA Baseline Treated Eyes VA Baseline Fellow Eyes AxL Treated Eyes AxL Fellow Eyes Lens Status Treated Eyes

  2017cites this paper
• Geographic Atrophy and Activity of Neovascularization in Retinal Angiomatous Proliferation.

  2016cites this paper
• Geographic Atrophy and Choroidal Neovascularization in the Same Eye: A Review

  2016cites this paper
• Intravitreal Anti-Vascular Endothelial Growth Factor for Retinal Pigment Epithelial Tear in Retinal Angiomatous Proliferation

  2016cites this paper
• Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Retinal Angiomatous Proliferation: A Review of the Literature and Therapeutic Considerations

  2016cites this paper
• Makula-Atrophie bei feuchter altersabhängiger Makuladegeneration

  2016cites this paper
• Retinal Pigment Epithelial Atrophy in Neovascular Age-Related Macular Degeneration After Ranibizumab Treatment.

  2016cites this paper
• Predictors of Macular Atrophy Detected by Fundus Autofluorescence in Patients With Neovascular Age-Related Macular Degeneration After Long-Term Ranibizumab Treatment.

  2016cites this paper
• Retinal Ganglion Cell Layer Change in Patients Treated With Anti-Vascular Endothelial Growth Factor for Neovascular Age-related Macular Degeneration.

  2016cites this paper
• Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians.

  2016cites this paper
• A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration.

  2016cites this paper
• [Atrophy of the macula in the context of its wet, age-related degeneration : An inescapable consequence of anti-VEGF therapy?]

  2016cites this paper
• Macular atrophy in patients with long‐term anti‐VEGF treatment for neovascular age‐related macular degeneration

  2016cites this paper
• TREAT-AND-EXTEND REGIMEN WITH AFLIBERCEPT FOR RETINAL ANGIOMATOUS PROLIFERATION

  2016cites this paper
• Regulation of signaling events involved in the pathophysiology of neovascular AMD

  2016cites this paper
• VEGF-B inhibits hyperglycemia- and Macugen-induced retinal apoptosis

  2016cites this paper
• Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).

  2016cites this paper
• Perspectives on reticular pseudodrusen in age-related macular degeneration.

  2016cites this paper
• Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration.

  2015cites this paper
• Short-Term Changes in Choroidal Thickness After Aflibercept Therapy for Neovascular Age-Related Macular Degeneration.

  2015cites this paper
• Two-year results of combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation

  2015cites this paper
• Type 1 neovascularization may confer resistance to geographic atrophy amongst eyes treated for neovascular age-related macular degeneration

  2015cites this paper
• TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations

  2015cites this paper